GU Cancers 2022 | Investigating the treatment of unselected mCRPC patients with a CDK 4/6 inhibitor plus abemaciclib

Arpit Rao, MD, Baylor College of Medicine, Houston, TX, talks on a phase II trial investigating the treatment of unselected metastatic castration-resistant prostate cancer (mCRPC) patients with the CDK 4/6 inhibitor, abemaciclib, plus the monoclonal antibody, atezolizumab. Robust preclinical data demonstrated the efficacy of this combination and treatment with CDK 4/6 inhibitors have been demonstrated to sensitize preclinical models to PD-L1 and PD-1 inhibiting agents. This trial is to explore whether these results can be translated to clinical practice. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.